UK’s NICE will cover $700K cost of GSK’s gene therapy; Evoke shares spike on NDA plans – Endpoints News
Endpoints News |
UK's NICE will cover $700K cost of GSK's gene therapy; Evoke shares spike on NDA plans
Endpoints News The UK's pharma price watchdog NICE has sanctioned coverage of GlaxoSmithKline's gene therapy Strimvelis for “bubble baby” syndrome, which costs about $700,000 for the once-and-done therapy. About three babies a year are born with ADA-SCID in the … |
